EPCAM and breast cancer: In a medium cohort of patients in previous studies, these findings revealed that ALDH1A3, PROCR, ITGA6+, ITGA6+/EpCAM− and ITGA6−/EpCAM+ were correlated with reduced RFS or overall survival of these breast cancer patients [35–37].